Last update 02 May 2024
Visirna Biotechnology (Shanghai) Co., Ltd.
2022|
Shanghai Shi, China
Last update 02 May 2024
Overview
Basic Info
Introduction Established in 2008, Visirna Biotechnology (Shanghai) provides one-stop comprehensive services ranging from early-stage structure-based drug development to commercial drug production for global innovative drug research and development companies. It has built several advanced technology platforms, including X-ray protein crystal technology, Cryo-EM, ASMS, SPR, HDX-MS, and computer-assisted drug design. Through its subsidiary, Langhua Pharmaceutical, Visirna provides a one-stop CMC/CDMO solution from preclinical development to commercial production. Additionally, Visirna focuses on discovering and investing in high-potential bio-pharmaceutical startups, employing a unique business model of Equity-for-Service (EFS) to address unmet clinical needs. |
Tags
Congenital Disorders
Other Diseases
Endocrinology and Metabolic Disease
Small interfering RNA
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
一项在中国成年非酒精性脂肪性肝炎（NASH）患者中评价VSA006注射液的疗效和安全性的多中心、随机双盲、安慰剂对照的II期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of VSA006 injection in Chinese adult patients with non-alcoholic steatohepatitis (NASH)
一项在中国家族性乳糜微粒血症综合征成人患者中评价VSA001注射液有效性和安全性的III期临床研究
[Translation] A phase III clinical study evaluating the efficacy and safety of VSA001 injection in Chinese adult patients with familial chylomicronemia syndrome
一项在中国健康成年志愿者中评价VSA001注射液单次给药的安全性、耐受性、药代动力学和药效学的随机、双盲、安慰剂对照I期临床研究
[Translation] A randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single administration of VSA001 injection in Chinese healthy adult volunteers
100 Clinical Results associated with Visirna Biotechnology (Shanghai) Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Visirna Biotechnology (Shanghai) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Visirna Biotechnology (Shanghai) Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 03 Jul 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
1
Phase 2 Clinical
Phase 3 Clinical
1
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free